Abstract:
Lennox-Gastaut Syndrome (LGS) is a severe form of epilepsy primarily affecting pediatric patients. Conventional antiepileptic drugs (AEDs) often fail to adequately control seizures in LGS, leading to a need for alternative treatment options. Cannabidiol (CBD), a non-psychoactive component of Cannabis sativa, has shown promise as a potential therapy for refractory epileptic syndromes. However, there is a scarcity of well-designed studies evaluating the role of CBD, specifically in LGS. This systematic review and meta-analysis aimed to assess the efficacy and safety of CBD for seizure control in pediatric patients diagnosed with LGS.A comprehensive search was conducted in multiple databases to identify relevant studies comparing CBD to placebo in LGS patients. Data extraction and quality assessment were performed, and a meta-analysis was conducted using Review Manager. The odds ratio (OR) and 95% confidence interval (CI) were calculated.Four studies met the inclusion criteria and were included in the meta-analysis. The pooled analysis demonstrated a significantly higher efficacy of CBD compared to placebo in achieving a 50% or more reduction in seizure frequency (OR 2.56; 95% CI, 1.89–3.48, P < 0.00001). Subgroup analysis revealed that the dosages of 10 mg/kg/day (OR 3.19; 95% CI, 1.92–5.29, P < 0.00001) and 20 mg/kg/day (OR 3.56; 95% CI, 2.46–5.14, P < 0.00001) showed significantly higher efficacy compared to the higher dosages of 25–50 mg/kg/day. Adverse events reported in the CBD group included somnolence, decreased appetite, and diarrhea, with a higher incidence of serious adverse events compared to the placebo group.CBD demonstrated significantly higher efficacy compared to placebo in achieving a 50% or greater reduction in seizure frequency. The dosage of CBD did not show a direct correlation with seizure control, emphasizing the need for individualized dosing. Although CBD is generally well tolerated, careful monitoring for adverse events is essential.
Page(s):
DOI:
DOI not available
Published:
Journal: Abstract Book on 9th Annual Neuroscience Conference (ANC-23) August 12-13, 2023 , Volume: 0, Issue: 0, Year: 2023